The study identifies a completely novel driver of systemic aging and introduces a small molecule that shows incredible synergy with rapamycin.
The molecule used in the paper is
2,3-dehydro-2-deoxy-N-acetylneuraminic acid
C9-BA-DANA (C9-butyl-amide-DANA) would probably be the best option as of now to use as it is the most extensively studied selective NEU1 inhibitor. It is over 200 times more selective for NEU1 than the other NEUs, demonstrating an IC50 of 10 µM for NEU1 but failing to inhibit the others even at 1000 µM. It has already been successfully tested in live mice to block NEU1-mediated inflammation
C9-BA-DANA paper:
Neuraminidase-1 (NEU1): Biological Roles and Therapeutic Relevance in Human Disease
Link to the anti aging paper:
Elastin-derived extracellular matrix fragments drive aging through innate immune activation
Here is a recent YouTube video about it:
This Tiny Molecule Blocks Aging
DANA + Rapamycin Show Massive Synergistic Anti-Aging Effects (17%+ Lifespan Extension)
A landmark study just published in Nature Aging identifies a completely novel driver of systemic aging — degraded elastin fragments circulating in our blood — and introduces a small molecule called DANA that blocks this pathway by inhibiting a transmembrane signaling protein called NEU1 (neuraminidase 1). On its own, DANA extended lifespan by up to 17% in naturally aged mice. Combined with rapamycin, the results were even more striking.
What’s Actually Driving the Aging?
As we age, our extracellular matrix (the structural scaffolding between cells) breaks down and releases protein fragments called matrikines into the bloodstream. The researchers measured four major types — elastin, hyaluronic acid, fibronectin, and collagen fragments — and found that all increase with age in both mice and humans. But elastin-derived fragments were by far the most damaging.
Within elastin fragments, a specific six-amino-acid sequence called the E-motif (VGVAPG) is the culprit. This motif activates monocytes and macrophages through the elastin receptor complex, where NEU1 acts as the signal transducer. The result is a cascade of chronic innate immune activation → inflammatory cytokine release (IL-1β, IL-6, MCP-1, TNF) → abnormal T and B cell expansion → full-blown systemic inflammaging. When they knocked out NEU1 specifically in myeloid cells, the entire aging cascade was abolished.
DANA Monotherapy in Naturally Aged Mice
DANA was given to wild-type, naturally aged mice (starting at ~60 weeks) via weekly intraperitoneal injection at 2.5 mg/kg. Results:
- Lifespan extension: +17.4% median lifespan in males, +12.2% in females
- Body composition: Significant reductions in body weight, fat mass, and abdominal fat with preserved lean tissue
- Mobility: Improved treadmill endurance, open-field locomotor activity, and grip strength
- Reduced kyphosis: Less spinal curvature (a classic aging phenotype)
- Liver health: Reduced hepatic steatosis, lower AST/ALT, and lower liver triglyceride content
- Metabolic markers: Improved glucose, LDL, and triglyceride levels
- Inflammaging: Broad suppression of 22 inflammatory markers measured in serum
DANA + Rapamycin Synergy
This is where it gets really exciting. They co-administered DANA (2.5 mg/kg) + rapamycin (6 mg/kg), both once weekly. The combination significantly outperformed either monotherapy across the board:
- Lifespan: The combo group lived significantly longer than DANA-only (p=0.02) and rapamycin-only (p=0.04) groups
- Body weight & composition: Greatest reduction in body weight and best fat-to-lean tissue ratio of any group
- Inflammation: Lowest IL-1β and MCP-1 levels — significantly better than either drug alone
- Tissue-level improvements: Largest muscle fiber increases, greatest WAT adipocyte shrinkage, and most liver triglyceride reduction
Notably, DANA and rapamycin work through completely different mechanisms — DANA blocks the matrikine/NEU1/innate immune axis while rapamycin targets mTOR — which likely explains why they synergize so well.
Validated in Pigs and Humanized Mice
They didn’t stop at mice. In Yorkshire pigs given E-motif injections twice weekly for 16 weeks, co-administration of DANA normalized markers of liver function (AST, ALP, albumin), kidney function (BUN, creatinine), and metabolic health (glucose, LDL, triglycerides). In immune-humanized mice injected with actual human elastin fragments, DANA produced nearly identical protective effects across the same biomarkers.
Human Cohort Data
Analysis of 1,068 human serum samples confirmed that circulating elastin fragment levels strongly correlate with age (p<0.0001) and are positively associated with BMI, hypertension, liver dysfunction, dyslipidemia, kidney impairment, hyperglycemia, chronic inflammation, and even mild thyroid dysfunction. Individuals in the “high elastin fragment” group had significantly worse outcomes across virtually every aging-related biomarker measured.
Safety & Dosing Considerations
- Dose used: 2.5 mg/kg once weekly (IP injection in mice and pigs)
- No reported adverse effects across any of the animal models
- DANA shares a parent molecular scaffold with FDA-approved neuraminidase inhibitors like zanamivir (Relenza) and oseltamivir (Tamiflu), which have well-established human safety profiles
- DANA works downstream of the elastin fragments themselves — it doesn’t immediately reduce circulating fragment levels, but long-term treatment gradually lowers them as the aging process slows